Prothena Presents First Clinical Data for PRX003 for the Treatment of Inflammatory Diseases

On June 10th, Prothena (NasdaqGS: PRTA) presented the first clinical results for PRX003 at the European League Against Rheumatism (EULAR) conference in London. PRX003 is the Company’s antibody development program targeting melanoma cell adhesion molecule (MCAM), which has been implicated in a range of inflammatory diseases. PRX003 targets pro-inflammatory T-helper 17 (Th17) cells, with the goal of preventing the release of multiple disease-causing cytokines. In the Phase I single ascending dose (SAD) trial in healthy volunteers, PRX003 was safe and well tolerated at all doses tested, and there was a dose-dependent down regulation of MCAM. Prothena is now moving into a Phase 1b, multiple ascending dose (MAD) trial that will test PRX003 in psoriasis patients. Data are expected in the second half of 2017. Here we provide details of the clinical update as well as in depth background information on PRX003, Th17 cells, and MCAM.

For full access, please click here.